| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.9 |